Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.27 and traded as high as $1.69. Cortexyme shares last traded at $1.67, with a volume of 132,622 shares trading hands.
Cortexyme Trading Up 7.7 %
The firm’s 50 day simple moving average is $1.82 and its 200 day simple moving average is $1.27. The firm has a market cap of $50.35 million, a PE ratio of -0.56 and a beta of 1.40.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
See Also
- Five stocks we like better than Cortexyme
- How Technical Indicators Can Help You Find Oversold Stocks
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Learn Technical Analysis Skills to Master the Stock Market
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
